Document:

Exhibit 10.18

 

EXECUTION COPY

 

Third Amendment To Development and Clinical Supplies Agreement*

 

This Amendment, dated September 29, 2010 by and between 3M Company, and 3M Innovative Properties Company having a principal office at 3M Center, Building 275-3E-10, St. Paul, MN  55144-1000 (hereinafter “3M”), and Radius Health Inc. having a principal office at 300 Technology Square, Cambridge, MA (hereinafter “Radius”) amends the Development and Clinical Supplies Agreement dated June 19, 2009  (hereinafter “the Agreement”) as follows:

 

RECITALS:

 

A.           Whereas, 3M and Radius have previously entered into a Development and Clinical Supplies Agreement dated June 19, 2009 for the development and delivery of clinical supplies up through Phase II for a BA058 coated MTS  product (“Product”) and have entered into a Second Amendment to the Agreement dated September 16, 2010 (the “Agreement”);

B.             Whereas, Radius also requires additional clinical supplies, including chronic dermal toxicology supplies

C.             Whereas, Radius  may require stability testing of any clinical or toxicology  supplies provided by 3M;

D.            Whereas, to meet Radius required timing, 3M must invest in additional facilities and equipment;

E.              Whereas Radius is willing to guaranty repayment of a portion of the planned work to enable 3M to justify its investment in the event that Radius does not expend certain additional sums with 3M under existing and future Workplans by Dec 20, 2011 ;

F.              Whereas, all terms of the Agreement not explicitly amended by this Amendment shall remain in full force and effect.  To the extent not modified or defined by this Amendment, all capitalized and defined terms shall have the meaning ascribed to them in the Agreement.

 

NOW, THEREFORE, in consideration of the Recitals (which are incorporated herein) and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to amend the Agreement as follows:

 

1.                                       3M shall provide approximately seven thousand five hundred (7,800) chronic dermal toxicology supplies (at two doses and Placebo) in amounts shown in the table below.  3M shall invoice Radius for such supplies on a time and material basis.  The estimated cost for the Chronic Dermal Toxicology supplies is $475,000.

 

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission.

 

1

 

The chronic dermal toxicology supplies will be produced in two runs. The first of each lot is targeted to be manufactured by January 1, 2011. The second of each lot is targeted to be completed by March 1, 2011.

 

	
 
    	
 
    	
100 mcg dose
    	
 
    	
200 mcg dose
    	
 
    	
Placebo
    
	
6 Month Tox
    	
 
    	
2,400
    	
 
    	
2,400
    	
 
    	
2,400
    
	
Extras
    	
 
    	
0
    	
 
    	
0
    	
 
    	
0
    
	
Retains
    	
 
    	
100
    	
 
    	
100
    	
 
    	
100
    
	
Release
    	
 
    	
55
    	
 
    	
55
    	
 
    	
40
    
	
Stability
    	
 
    	
250
    	
 
    	
250
    	
 
    	
0
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Needed Arrays
    	
 
    	
2,805
    	
 
    	
2,805
    	
 
    	
2,540
    

 

2.                                       3M shall conduct a stability protocol on the two doses of the chronic dermal toxicology supplies. The stability protocol shall include two storage conditions: 5C/ambient humidity with two (2) pulls (6 and 12 months), not including release, and 25C/60%RH with a single pull at one (1) month. 3M shall also conduct a limited stability protocol on the ready-to-coat (RTC) solutions for the chronic dermal toxicology supplies.  The stability protocol shall include one storage condition: 5C/ambient humidity with five (5) pulls (1,2,3,4 and 6 months) for each solution. The RTC solution will also be tested prior to each manufacturing run for confirmation of formulation. 3M shall invoice Radius Three Thousand Six Hundred Dollars ($3,600) per pull point for stability testing at the conclusion of testing of the each pull for any requested stability work.

 

3.                                       Radius understands that for 3M to meet Radius’ requirements under paragraph 1.3M will need to invest in additional facilities and equipment and that the expected revenue from providing these requirements is not sufficient to cover 3M’s investment.  Therefore, Radius agrees that if Radius does not fund at least $1.8 million of work under existing and future Workplans, including the cost of  supplies above and the $85,000 payment made pursuant to the Second Amendment to the Agreement dated September 16, 2010, starting after the effective date of this Amendment and ending by no later than December 20, 2011, or if Radius terminates the Agreement without cause or 3M terminates the Agreement for cause and at the time of such termination or expiration Radius has not expended an aggregate $1.8 million of work during the period from the effective date of this Amendment until the effective date of termination, 3M shall invoice Radius any shortfall from this amount by December 31, 2011 and Radius shall pay 3M unless otherwise agreed by 3M.

 

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission.

 

2

 

4.                                       Notwithstanding the foregoing, in the event that the results from Radius Phase Ia study from either application sites (the thigh or the abdomen) meet the criterion listed below, Radius shall be obligated to pay for any shortfall under the circumstances set forth in paragraph 3.

Criteria for Phase Ia results:

 

·                  Cmax of low dose OR mid dose will be equal to or exceed 95% of the Cmax associated with the 80 mcg SC dose

·                  Cmax of mid dose OR high dose will be equal to or exceed 125% of the Cmax associated with the 80 mcg SC dose

 

5.                                       Except to the extent expressly amended by this Third Amendment, all of the terms, provisions and conditions of the Agreement are hereby ratified and confirmed and shall remain in full force and effect.  The term “Agreement”, as used in the Agreement, shall henceforth be deemed to be a reference to the Agreement as amended by this Third Amendment.

 

6.                                       This Third Amendment may be executed in counterparts, each of which will be deemed an original with all such counterparts together constituting one instrument.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed in duplicate as of the date and year the last Party signs below.

 

ACCEPTED AND AGREED TO:

 

	
3M COMPANY
    	
 
    	
Radius Health Inc.
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By
    	
/s/ Jim A. Vaughan
    	
 
    	
By
    	
/s/ B. N. Harvey 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Print Name
    	
Jim A. Vaughan
    	
 
    	
Print Name
    	
B. N. Harvey 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title
    	
Division VP & GM
    	
 
    	
Title
    	
SVP and CFO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date
    	
10/7/2010
    	
 
    	
Date
    	
September 29, 2010
    

 

 

3M INNOVATIVE PROPERTIES COMPANY

 

 

	
By
    	
/s/ Robert W. Sprague
    	
 
    
	
 
    	
 
    	
 
    
	
Print Name
    	
Robert W. Sprague
    	
 
    

 

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed Separately with the Commission.

 

3

 

	
Title
    	
Secretary
    	
 
    
	
 
    	
 
    	
 
    
	
Date
    	
October 5, 2010
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
ACR # 201004143
    	
 
    

 

4Exhibit 10.19 

 

Change Order Form - Amendment 5*

 

Change order under Agreement dated: Development and Clinical Supply Agreement dated 19 June 2009

 

Between: Radius Health and 3M

 

Project Name: Radius Health proprietary compound BA058 and 3M proprietary microstructured transdermal system

 

Change requested by: Radius

 

Name:  Maria Grunwald

Company:  Radius Health, Inc

Date:   4 February 2011

 

Description of change:  Radius has asked 3M to prepare three Workplans that identify activities that could be initiated in February 2011.  These activities are summarized on the following Workplans:

 

Workplan #1 — Microscopic Evaluation of Clinical Supplies Workplan Summary

Workplan #2 — Residual Drug Analysis of Clinical Supplies Workplan Summary

Workplan #3 — Optimization of Ready-to-Coat Formulation and Process and Method  Development for Product Development Workplan Summary

Workplan #4 — DMF preparation for FDA response

 

In addition to the Workplans listed above, 3M will deliver responses to the FDA Advice/Information letter for the sMTS development received by Radius. These responses incorporate current testing plans (Workplan #1, #2, current manufacturing plan, in process controls, and the depth of penetration) & planned future development plan (i.e., DMFs development and sterile manufacturing process).  For the avoidance of doubt, 3M will provide Radius information on the depth of penetration studies funded by 3M at no charge to Radius.  The current responses to the FDA letter, and any authorized work, and reports conducted under the Workplans #1 and #2 will be completed by 3M and delivered to Radius by the end of February 2011 for Radius’ response submission.

 

Radius authorizes 3M to work up to a maximum of [*] hours at a rate of $[*] per hour in February under this change order.  Radius will prioritize the Workplans #1 and #2, and in the case of Workplan  #3, Radius will advise which tasks that it wishes 3M to commence in

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

1

 

February to complete the [*] authorized hours.  Radius understands that the deliverables accomplished under Workplan #3 will correlate to the amount of work authorized by Radius.

 

In all other respects, the terms and conditions of the Agreement remain in full force and effect.

 

Requested task, dates and costs are approved by:

 

	
Company: Radius
    	
3M
    
	
Name: Nick Harvey
    	
Name:   Mary Mathisen
    
	
Signature:
    	
/s/   B.N. Harvey
    	
 
    	
Signature:
    	
/s/ Mary   Mathisen
    
	
Position:   CFO
    	
Position: Commercialisation Mgr
    
	
Date (dd/mm/yy): February 4,   2011
    	
Date   (dd/mm/yy):4 February 2011
    
					

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

2

 

Workplan #1

 

MICROSCOPIC EVALUATION WORK PLAN SUMMARY

 

Objective:

 

The objective of the work plan is to perform microscopic evaluation BA058-sMTS patches and arrays to assess for microneedle fracture, deformation of the needle, residual drug, or biological matter deposits following removal from dosed clinical subjects of Period 2, Protocol BA058-05-006.

 

Scope:

 

Approximately 49 patches (controls and samples) will be evaluated microscopically. Group 2a, Day 4 and Day 5 BA058-sMTS samples of each subject ([*]mcg) removed following dosing will be sent for residual drug analysis. Group 2b, Day 4 and Day 5 BA058-sMTS samples of each subject (Placebo and [*]mcg) removed following dosing will be send for residual drug analysis. Group 2c, Day 4 and Day 5 BA058-sMTS samples of each subject ([*]mcg) removed following dosing will be sent for residual drug analysis. Three BA058-sMTS unused samples from each dose (Placebo, [*]mcg, and [*]mcg) will be used as controls. Each BA058-sMTS will be examined at 100x power by microscope and assessed for microneedle fracture (breaks, cracks, and chips), deformation of the needle (bends and/or blunting), residual drug, or biological matter deposits.

 

Materials:

 

Forceps

Microscope, capable of 100x magnification and equipped with a digital camera

Control and sample patches (Placebo, [*]mcg, and [*]mcg) currently stored at 2-8°C.

 

Procedure:

 

Placebo Controls;

 

1.               Remove samples from 2-8°C and allow the sample to reach room temp. (about 1 hour).

 

2.               Carefully remove one of the BA058-sMTS placebo patches from the collar.

 

PATCHES THAT ARE DISLODGED FROM THE COLLAR DURING SHIPPING WILL NOT BE ASSAYED.

 

3.               Using 100x magnification examine the patch and array for microneedle fracture, deformation of the needle, residual drug, or biological matter deposits.

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

3

 

4.               Document observations on Attachment 2.

 

5.               Photograph the damaged needles.

 

6.               Repeat 1 through 5 for the other BA058-sMTS placebo controls.

 

Repeat the above for the BA058-sMTS Placebo samples, [*]mcg controls, [*]mcg samples, [*]mcg controls and [*]mcg samples.

 

Projected Hours

 

Visual testing of 49 arrays                  [*] hours

Preparation, review, and release of report        [*] hours

Total Hours           [*]

 

Deliverables

 

A summary report describing the type and frequency of observations.

 

Attachments:

 

Example Photo

Observations

Summary Observations

 

Example Photo

 

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

4

 

OBSERVATIONS

 

Sample ID:

 

 

Describe appearance of patch:

 

5

 

Enter code for damaged array on to chart.

 

Codes: R — break, C — chip, K — crack, D — bend, L — blunt, B — biological matter, F — partial fill, S - residual drug

 

Add sequence number for digital image.

 

SUMMARY OBSERVATIONS

 

	
Sample
   ID
    	
 
    	
Microneedle fracture
   (breaks, cracks, and
   chips)
    	
 
    	
Deformation of
   the needle (bends
   and/or blunting)
    	
 
    	
Residual
   drug
    	
 
    	
Biological
   matter
   deposits
    	
 
    	
Digital
   Photo
    (√)
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

6

 

	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Breaks
    	
 
    	
Cracks
    	
 
    	
Chips
    	
 
    	
Bends
    	
 
    	
Blunting
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    

 

7

 

Workplan #2

 

RESIDUAL DRUG ANALYSIS WORK PLAN SUMMARY

 

Objective:

 

The objective of the work plan is to perform residual drug analysis of BA058-sMTS arrays following removal from dosed clinical subjects of Period 2, Protocol BA058-05-006 to assess residual drug remaining on the array.

 

Scope:

 

Approximately 49 arrays (controls and samples) will be evaluated for residual drug. Group 2a, Day 6 and Day 7 BA058-sMTS samples of each subject ([*] mcg) removed following dosing will be sent for residual drug analysis. Group 2b, Day 6 and Day 7 BA058-sMTS samples of each subject (Placebo and [*]mcg) removed following dosing will be send for residual drug analysis. Group 2c, Day 6 and Day 7 BA058-sMTS samples of each subject ([*] mcg) removed following dosing will be sent for residual drug analysis. Three BA058-sMTS unused samples from each dose (Placebo, [*] mcg, and [*] mcg) will be used as controls. Each BA058-sMTS will be analyzed in accordance with Method-07-001836.

 

Materials:

 

Forceps

Snap-cap polypropylene sample vials (5mL, Nalgene Part 6250-0005)

BA058-sMTS Control and sample patches (Placebo, [*] mcg, and [*] mcg) stored at -20°C.

 

Procedure:

 

Prepare the controls and samples as follows;

 

7.               Remove samples from -20°C storage and allow to reach room temp. (approx. 2 hours).

 

8.               Carefully remove one of the BA058-sMTS patches from the collar.

 

PATCHES THAT ARE DISLODGED FROM THE COLLAR DURING SHIPPING WILL NOT BE ASSAYED.

 

9.               Separate the large circular adhesive from the hard plastic disc containing the micro array needles by holding the array patch across the patch diameter with the thumb and finger.

 

DO NOT TOUCH THE MICRO ARRAY.

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

8

 

10.         Pinch the thumb and finger together to bend the patch away from the array. (Figure A).

 

Figure A.               Use the forceps to grab the array from the bent adhesive patch.

 

 

11.         Use a forceps to grasp the array and to peel the array from the patch (Figure A).

 

12.         Place the disc containing the micro array into a labeled plastic snap cap container (needles-down orientation) and seal.

 

13.         Analyze each in accordance with Method-07-001836.

 

Projected Hours

 

	
HPLC analysis and review of data for 49 patches
    	
 
    	
[*]   hours
    
	
Preparation, review, and release of report
    	
 
    	
[*]   hours
    
	
Total
    	
 
    	
[*]   hours
    

 

Deliverables

 

Summary report describing residual BA058 content of arrays.

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

9

 

Workplan #3

 

RTC Process Development and Analytical Methods WORK PLAN SUMMARY

 

Objective

 

Determine operating conditions for RTC mixing and filtration that provide a robust process for preparing sterile, homogeneous ready-to-coat (RTC) formulation.  Following these experiments, the process and parameters for preparing RTC should be finalized.

 

Some method development efforts are also addressed below.

 

Background

 

[*]  Consequently, the RTC formulation is prepared by using a [*].  This results in a very inhomogeneous formulation that needs to be thoroughly mixed prior to sterile filtration.  Currently, the RTC is [*] for [*] prior to sampling.   An additional [*] of [*] does not appear to effect the concentration, but limited data is available at this time point[*] after the filtration step appears to substantially improve the consistency of the RTC.

 

Process efficiency is currently about [*].  Variations in filtration media and devices will be investigated to improve this number.

 

Scope

 

Observed response variables for the mixing experiments are average content, variance of the content, and viscosity.  Two mixing methods will be investigated: [*] (the current method) and [*], a [*].  For [*], three times ([*],[*],[*]min) prefiltration and four times ([*],[*],[*],[*] minutes) postfiltration will be tested.  For [*], three times will be investigated prefiltration ([*],[*],[*] minutes) and four times postfiltration ([*],[*] ,[*], and [*] minutes).    To investigate the effect of the RTC concentration, mixing will be performed with [*]% and [*]% bulk drug substance (w/w).  The current manufacturing process uses [*]% w/w.

 

Only one lot of BA058 will be used.  Any variability due to the lot of BA058 should be minimal due to controls on its composition.

 

Materials

 

14 g BA058

Miscellaneous lab supplies

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

10

 

Procedure

 

For each mixing technique, the prefiltration experiments will be performed.  The best prefiltration mixing time will be used for the postfiltration experiments.  The procedure will be repeated for the two concentrations of BA058.

 

The average and variance of the content will be determined by taking multiple samples from each mixing experiment and assayed using a validated HPLC method (Method-07-001836).   Viscosity of the RTC following each experiment will be tested using a Rheosense m-VROC.

 

Each experiment will use [*]  mL of RTC ([*] g of bulk drug substance).  Smaller volumes would not be indicative of performance at larger scales, and larger amounts result in exessive consumption of BA058.  The 14 g figure is considerably larger than previously quoted.  The previous quote assumed material could be saved by using the RTC from the mixing experiments to begin the coating process experiments.  Of course, unused RTC from this work will be saved for future use.

 

To determine the optimal approach to sterile filtration, a solution of BSA will be prepared with a viscosity similar to that of the current RTC.  This solution will be used to test filtration setups for easy of use and efficiency.  Once a suitable configuration is found, it will be tested by sterile filtering RTC and checking for changes in viscosity, purity, and content.

 

Projected Hours

 

Mixing Process Development

 

	
Perform   mixing and take samples
    	
 
    	
[*]   hours
    
	
HPLC   analysis
    	
 
    	
[*]   hours
    
	
Viscosity   measurements
    	
 
    	
[*]   hours
    
	
Prepare   report
    	
 
    	
[*]   hours
    
	
Mixing   Process Total
    	
 
    	
[*]   hours
    

 

Filtration Process Development

 

	
Trial   filtration runs
    	
 
    	
[*]   hours
    
	
Confirm   filtration parameters
    	
 
    	
[*]   hours
    
	
Prepare   reports
    	
 
    	
[*]   hours
    
	
Filtration   Process Total
    	
 
    	
[*]   hours
    
	
RTC   Process Development Total
    	
 
    	
[*]   hours
    

 

Deliverables

 

1.               Summary report describing mixing experiments

2.               Summary report describing filtration experiments

3.               Master Batch Record for the ready to coat

4.               Updated specifications for the ready to coat

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

11

 

Analytical Method Development

 

The following analytical method development activities are proposed. Method development covers laboratory activities intended to define the method. Authoring of method development reports and validation activities are separate and not included in the estimates given here.

 

	
Identification   method
    	
 
    	
Uses   current HPLC method, mix 1:1 sample with reference material, show that only   one peak elutes from HPLC. Update method document.
    	
 
    	
[*] hours
    
	
Aggregation   method
    	
 
    	
Develop   size exclusion chromatography method to characterize any formation of   aggregates in drug product
    	
 
    	
[*] hours
    
	
Release   Method
    	
 
    	
Explore   and develop method for release testing of microneedle patches.
    	
 
    	
[*] hours
    
	
Pouch   Integrity
    	
 
    	
Adapt   ASTM method to microneedle patches
    	
 
    	
[*] hours
    
	
Patch   Adhesion
    	
 
    	
Adapt   ASTM method to microneedle patches
    	
 
    	
[*] hours
    

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

12

 

Workplan #4

 

FDA RESPONSE WORK PLAN SUMMARY

 

Objective:

 

Respond to FDA’s questions regarding 3M’s manufacturing process and controls.

 

Scope:

 

A DMF will be prepared with information about 3M’s sMTS manufacturing process and controls.

 

Materials:

 

Not Applicable

 

Procedure:

 

Not Applicable

 

Projected Hours

 

	
Prepare,   review, and submit DMF
    	
 
    	
[*]   hours
    

 

Deliverables

 

1)              DMF will be filed with FDA.

2)              Radius will be provided with the DMF number and a letter of access.

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

13

 

3M DRUG DELIVERY SYSTEMS CONTACT INFORMATION

 

For inquiries related to the proposal, please contact:

 

Mary Mathisen

Product Commercialization Manager

3M Drug Delivery Systems

3M Center, Bldg. 260-4N-12

St. Paul, MN 55144

Tel:  651-733-9125

Fax:  651-575-1729

Cell: 617-503-0861

E-Mail: mmathisen@mmm.com

 

Mark Tomai Ph.D.

Head of Vaccine Business

3M Drug Delivery Systems

3M Center, Bldg. 275-3E-10

St. Paul, MN 55144

Tel:  617-733-5375

Cell: 651-403-0455

E-Mail: matomai@mmm.com

 

* Confidential Treatment Requested by the Registrant.  Redacted Portion Filed Separately with the Commission.

 

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]